Literature DB >> 22007676

Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Geetanjali Agnihotri1, Breanna M Crall, Tyler C Lewis, Timothy P Day, Rajalakshmi Balakrishna, Hemamali J Warshakoon, Subbalakshmi S Malladi, Sunil A David.   

Abstract

Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine (PAM(2)CS) compounds are potential vaccine adjuvants. In continuation of previously reported structure-activity relationships on this chemotype, we have determined that at least one acyl group of optimal length (C(16)) and an appropriately oriented ester carbonyl group is essential for TLR2-agonistic activity. The spacing between one of the palmitoyl ester carbonyl and the thioether is crucial to allow for an important H-bond, which observed in the crystal structure of the lipopeptide:TLR2 complex; consequently, activity is lost in homologated compounds. Penicillamine-derived analogues are also inactive, likely due to unfavorable steric interactions with the carbonyl of Ser 12 in TLR2. The thioether in this chemotype can be replaced with a selenoether. Importantly, the thioglycerol motif can be dispensed with altogether and can be replaced with a thioethanol bridge. These results have led to a structurally simpler, synthetically more accessible, and water-soluble analogue possessing strong TLR2-agonistic activities in human blood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22007676      PMCID: PMC3228886          DOI: 10.1021/jm201071e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

Review 1.  Controlling the Toll road to dendritic cell polarization.

Authors:  Alessandra Mazzoni; David M Segal
Journal:  J Leukoc Biol       Date:  2004-01-14       Impact factor: 4.962

2.  TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23.

Authors:  Ehsan Aliahmadi; Robert Gramlich; Andreas Grützkau; Manuel Hitzler; Melanie Krüger; Ria Baumgrass; Maximilian Schreiner; Burghardt Wittig; Reinhard Wanner; Matthias Peiser
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

Review 3.  Potential adjuvantic properties of innate immune stimuli.

Authors:  Hemamali J Warshakoon; Jennifer D Hood; Matthew R Kimbrell; Subbalakshmi Malladi; Wen Yan Wu; Nikunj M Shukla; Geetanjali Agnihotri; Diptesh Sil; Sunil A David
Journal:  Hum Vaccin       Date:  2009-06-16

Review 4.  Structures of TLR-ligand complexes.

Authors:  Mi Sun Jin; Jie-Oh Lee
Journal:  Curr Opin Immunol       Date:  2008-07-02       Impact factor: 7.486

5.  Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway.

Authors:  O Takeuchi; A Kaufmann; K Grote; T Kawai; K Hoshino; M Morr; P F Mühlradt; S Akira
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

Review 6.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

Review 7.  From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development.

Authors:  Anne O'Garra; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2009-09       Impact factor: 25.606

8.  Controlling plasma protein binding: structural correlates of interactions of hydrophobic polyamine endotoxin sequestrants with human serum albumin.

Authors:  Thuan B Nguyen; E V K Suresh Kumar; Diptesh Sil; Stewart J Wood; Kelly A Miller; Hemamali J Warshakoon; Apurba Datta; Sunil A David
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

9.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

Review 10.  Toll-like receptors and T-helper-1/T-helper-2 responses.

Authors:  Karim Dabbagh; David B Lewis
Journal:  Curr Opin Infect Dis       Date:  2003-06       Impact factor: 4.915

View more
  26 in total

1.  Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.

Authors:  Veronika Mäde; Kathrin Bellmann-Sickert; Anette Kaiser; Jens Meiler; Annette G Beck-Sickinger
Journal:  ChemMedChem       Date:  2014-08-22       Impact factor: 3.466

2.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

Review 3.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

4.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

5.  TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

Authors:  Nicholas J Laping; Michael P DeMartino; Joshua E Cottom; Jeffrey M Axten; John G Emery; Jeffrey H Guss; Miriam Burman; James J Foley; Mui Cheung; Allen Oliff; Sanjay Kumar
Journal:  Blood Adv       Date:  2017-12-08

6.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

7.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

8.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

9.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Authors:  Amanda B Macedo; Camille L Novis; Caroline M De Assis; Eric S Sorensen; Paula Moszczynski; Szu-Han Huang; Yanqin Ren; Adam M Spivak; R Brad Jones; Vicente Planelles; Alberto Bosque
Journal:  JCI Insight       Date:  2018-10-04

10.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.